Insomnia Market

Increasing Work Stress Due to a Highly Competitive Lifestyle of Individuals will Increase the Insomnia Condition

The Insomnia Market is valued at USD 5.6  Bn in 2026 and is projected to reach USD 9.1  Bn,  growing at a CAGR of 7% by 2033. Irregular work shifts have an impact on the quality and cycle of sleep. According to WHO, 264 million people suffer from depression, which is mainly caused by work-related stress. Such a large pool of patients is likely to experience insomnia, which is anticipated to drive demand for effective insomnia treatment, thereby fuelling the growth of insomnia market. Moreover, the COVID-19 pandemic caused employment losses for many individuals as industries failed to function correctly, contributing to an increase in stress among people.  According to ILO, in 2020, there were record global job losses of 114 million jobs compared to 2019. This has caused an increase in the stress level of the individuals during the pandemic period, resulting in the growth of the insomnia market.

Orexin Antagonist Segment is Anticipated to Dominate Insomnia Treatment Type due to Minimal Side Effects

Orexin Antagonist segment is expected to grow within the forecast period. Suvorexant (MK-4305, Merck) is the first in a new class of insomnia medications known as ORAs (orexin receptor antagonists). By suppressing the arousal system's wakefulness-promoting orexin neurons, the aid of the tablets in the natural shift from restlessness to sleep. Suvorexant promotes the onset and maintenance of sleep. This separate option has favourable permissibility and a limited side-effect profile. The mechanism of action of suvorexant differs from that of benzodiazepines and non-benzodiazepines since it has no effect on Gamma-aminobutyric acid (GABA). It deactivates wakefulness rather than encouraging sleep. For instance, the US Food and Medication Administration (FDA) approved the new drug application for Easai's in-house discovered and developed orexin receptor antagonist DAYVIGOTM in December 2019. (lemborexant). DAYVIGO was licensed for the treatment of adult insomnia characterised by sleep onset and/or sleep maintenance issues. Due to developments in this class of medications, the segment is likely to grow steadily over the forecast period.

North America Dominant Insomnia Market with the Largest Patient Pool

The insomnia market has been dominated by North America. Over the projected period, the insomnia market here will be driven by the growing need for sleep disorder treatment in the United States and Canada, as well as the rising prevalence of sleep disorders. Additionally, the presence of sleep-related support groups in the country is a major driving factor for the industry. The Canadian Sleep Society is one such national organization dedicated to improving sleep for all Canadians by funding research, promoting high-quality clinical care, educating professionals and the public, and advocating for sleep and sleep disorders medicine. Furthermore, the presence of leading market competitors, as well as the R&D of new pharmaceuticals and product releases, are projected to drive the expansion of insomnia market under consideration.

The United States dominated North America due to the presence of the most sleep-deprived people and the usage of patented medications for therapy. Factors like adverse effects from certain OTC and prescription medications, arthritis, and excessive use of media devices before sleep are increasing the number of people suffering from insomnia, improving the prospects of the regional insomnia market. According to Cleveland Clinic, approximately 70 million American citizens suffer from insomnia out of which 50 percent are adults and 10-15% are children. Moreover, the increase in psychological circumstances and the steady increase in noise levels in the areas due to continuous infrastructure development will drive the insomnia treatment market throughout the projection period.

Asia-Pacific will continue to be a profitable region for the growth of the insomnia industry. The market expansion in the region may be highly ascribed to the increased stress level of the working population combined with shift-work-related sleep disorders. Governments in the region are always working to improve their healthcare systems and provide advantageous reimbursement policies, which may have an impact on the regional insomnia market. Over the next few years, developing countries such as China and India are likely to see an increase in demand for healthcare facilities and sleep aids. This would eventually open a slew of chances for top manufacturers looking to grow into these regional markets and gain a larger portion of the market. Japan is projected to dominate in Asia-Pacific due to technical improvements to offer unique treatment solutions for specific conditions. As per the survey carried out in Japan by a reputed organization, 49.3 percent of 10,000 participants in the survey were suffering from Insomnia which may indicate that around 50 percent of the Japanese populace is suffering from Insomnia. This factor is likely to drive regional growth in the coming years.

Global Insomnia Market: Competitive Landscape

Sector participants are presenting new products and developing collaborations, alliances, and partnership agreements. For instance, in February 2021, Eisai Limited, Eisai Inc.'s Canadian affiliate, acquired Canadian approval for its new non-sedative prescription drug, DAYVIGO (lemborexant). DAYVIGO, which is available in 5 mg and 10 mg doses, is recommended for the treatment of insomnia, which is characterized by difficulties with sleep start and/or sleep maintenance. For instance, in January 2021, Royalty Pharma plc and Minerva Neurosciences Inc. reached an agreement in which Royalty Pharma will buy Minerva's royalty stake in suvorexant. Seltorexant, a selective orexin 2 receptor antagonist, is now in Phase 3 development for the treatment of the major depressive disorder (MDD) symptoms associated with sleeplessness.

Few of the players in the Insomnia Market include 

• Eisai Co., Ltd.
• Idorsia Ltd.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Vanda Pharmaceuticals Inc.
• Sumitomo Pharma Co., Ltd.
• Reddy’s Laboratories Ltd.
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Zydus Lifesciences Ltd.
• Jazz Pharmaceuticals plc

Global Insomnia Market is Segmented as Below:

By Therapy Type

• Pharmacological Therapy
• Non-pharmacological Therapy

By Drug Class

• Benzodiazepines
• Non-benzodiazepines
• Melatonin Receptor Agonists
• Orexin Receptor Antagonists
• Antidepressants
• Antihistamines
• Herbal & Natural Sleep Aids
• Others

By Disease Type

• Acute Insomnia
• Chronic Insomnia
• Comorbid Insomnia
• Onset Insomnia
• Maintenance Insomnia

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User

• Hospitals
• Sleep Clinics
• Homecare Settings
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa